|
EP2600901B1
(en)
|
2010-08-06 |
2019-03-27 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
|
MX2013003681A
(es)
|
2010-10-01 |
2013-11-20 |
Moderna Therapeutics Inc |
Ácidos nucleicos manipulados y métodos de uso de los mismos.
|
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
|
HK1199736A1
(en)
*
|
2011-08-26 |
2015-07-17 |
箭头研究公司 |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
EP3640332A1
(en)
|
2011-08-29 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9428535B2
(en)
|
2011-10-03 |
2016-08-30 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
SMT202200355T1
(it)
|
2011-12-16 |
2022-11-18 |
Modernatx Inc |
Composizioni di mrna modificato
|
|
US8796405B2
(en)
*
|
2012-01-18 |
2014-08-05 |
Wisconsin Alumni Research Foundation |
Degradable polycations derived from amino acid vinyl esters
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
EP2834260A4
(en)
|
2012-04-02 |
2016-08-10 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US8933047B2
(en)
*
|
2012-04-18 |
2015-01-13 |
Arrowhead Madison Inc. |
Poly(acrylate) polymers for in vivo nucleic acid delivery
|
|
EP2922554B1
(en)
|
2012-11-26 |
2022-02-23 |
ModernaTX, Inc. |
Terminally modified rna
|
|
HK1214301A1
(zh)
|
2013-02-28 |
2016-07-22 |
箭头研究公司 |
治療epas1相關疾病的有機組合物
|
|
IL303425A
(en)
*
|
2013-03-13 |
2023-08-01 |
Cour Pharmaceuticals Dev Company |
Secondary vaccine particles for the treatment of inflammation
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
HUE050394T2
(hu)
|
2013-05-01 |
2020-11-30 |
Ionis Pharmaceuticals Inc |
Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények
|
|
EP3030244B1
(en)
|
2013-08-07 |
2021-04-21 |
Arrowhead Pharmaceuticals, Inc. |
Polyconjugates for delivery of rnai triggers to tumor cells in vivo
|
|
CA2923029A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
|
US9926556B2
(en)
|
2014-04-28 |
2018-03-27 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
KR20200102553A
(ko)
|
2014-05-01 |
2020-08-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
|
|
AU2015252895B2
(en)
|
2014-05-01 |
2021-07-15 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
CN106232804B
(zh)
|
2014-05-01 |
2019-10-25 |
Ionis制药公司 |
用于调节补体因子b表达的组合物和方法
|
|
EP4534092A3
(en)
|
2014-05-01 |
2025-07-02 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating pkk expression
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
MX2017014641A
(es)
|
2015-05-29 |
2018-01-23 |
Arrowhead Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
|
|
AU2016294347B2
(en)
|
2015-07-10 |
2022-07-28 |
Ionis Pharmaceuticals, Inc. |
Modulators of diacyglycerol acyltransferase 2 (DGAT2)
|
|
JP7336191B2
(ja)
|
2015-08-07 |
2023-08-31 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
Ｂ型肝炎ウイルス感染に対するＲＮＡｉ療法
|
|
RU2018113709A
(ru)
|
2015-09-24 |
2019-10-30 |
Айонис Фармасьютикалз, Инк. |
Модуляторы экспрессии kras
|
|
JOP20210043A1
(ar)
|
2015-10-01 |
2017-06-16 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
CN118846026A
(zh)
|
2015-10-22 |
2024-10-29 |
摩登纳特斯有限公司 |
广谱流感病毒疫苗
|
|
TN2018000152A1
(en)
|
2015-10-22 |
2019-10-04 |
Modernatx Inc |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
JP6921833B2
(ja)
|
2015-10-22 |
2021-08-18 |
モデルナティーエックス， インコーポレイテッド |
ヒトサイトメガロウイルスワクチン
|
|
AU2016342049B2
(en)
|
2015-10-22 |
2023-05-18 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
JP7687767B2
(ja)
|
2015-10-22 |
2025-06-03 |
モデルナティエックス インコーポレイテッド |
呼吸器合胞体ウイルスワクチン
|
|
EP4349405A3
(en)
|
2015-10-22 |
2024-06-19 |
ModernaTX, Inc. |
Respiratory virus vaccines
|
|
EP3370708A4
(en)
|
2015-11-06 |
2019-06-26 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF APOLIPOPROTEIN (A) EXPRESSION
|
|
FI4119569T3
(fi)
|
2015-11-06 |
2024-08-30 |
Ionis Pharmaceuticals Inc |
Konjugoituja antisense-yhdisteitä käytettäviksi hoidossa
|
|
LT3394093T
(lt)
|
2015-12-23 |
2022-04-25 |
Modernatx, Inc. |
Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
|
|
WO2017120612A1
(en)
|
2016-01-10 |
2017-07-13 |
Modernatx, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
US10246709B2
(en)
|
2016-03-07 |
2019-04-02 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
|
CN109526222B
(zh)
|
2016-06-06 |
2022-04-29 |
箭头药业股份有限公司 |
5’-环膦酸酯修饰核苷酸
|
|
MX2019000619A
(es)
|
2016-07-15 |
2019-08-01 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la modulacion de smn2.
|
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
|
CN116942841A
(zh)
|
2016-09-02 |
2023-10-27 |
箭头药业股份有限公司 |
靶向配体
|
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
TWI826365B
(zh)
|
2017-01-10 |
2023-12-21 |
美商愛羅海德製藥公司 |
α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法
|
|
CN119548520A
(zh)
|
2017-01-30 |
2025-03-04 |
箭头药业股份有限公司 |
用于抑制因子xii基因表达的组合物和方法
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
|
CR20190572A
(es)
|
2017-07-06 |
2020-05-23 |
Arrowhead Pharmaceuticals Inc |
AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
|
|
CA3073211A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
PE20201283A1
(es)
|
2017-09-11 |
2020-11-24 |
Arrowhead Pharmaceuticals Inc |
Agentes de iarn y composiciones para inhibir la expresion de la apolipoproteina c-iii (apoc3)
|
|
SG11201912188RA
(en)
|
2017-09-14 |
2020-01-30 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
|
|
AU2018352379A1
(en)
|
2017-10-17 |
2020-06-04 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
|
|
BR112020014425A2
(pt)
|
2018-01-15 |
2020-12-29 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão de dnm2
|
|
WO2019157531A1
(en)
|
2018-02-12 |
2019-08-15 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
CR20200605A
(es)
|
2018-05-09 |
2021-01-29 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la reducción de la expresión de fxi
|
|
WO2020018558A1
(en)
|
2018-07-17 |
2020-01-23 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
WO2020033748A1
(en)
|
2018-08-08 |
2020-02-13 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
|
TWI869213B
(zh)
|
2018-09-19 |
2025-01-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
AU2019403447B2
(en)
|
2018-12-21 |
2023-07-27 |
Ionis Pharmaceuticals, Inc. |
Modulators of HSD17B13 expression
|
|
KR20210113273A
(ko)
|
2019-01-09 |
2021-09-15 |
애로우헤드 파마슈티컬스 인코포레이티드 |
HIF-2 알파 (EPAS1)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
|
|
AU2020219355A1
(en)
|
2019-02-07 |
2021-09-30 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for Hepatitis B virus infection
|
|
KR20220042116A
(ko)
|
2019-06-18 |
2022-04-04 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
|
|
US20220305107A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
|
CN114728017B
(zh)
|
2019-10-14 |
2025-10-28 |
阿斯利康(瑞典)有限公司 |
Pnpla3表达的调节剂
|
|
BR112022016238A2
(pt)
|
2020-02-28 |
2022-10-11 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para modular smn2
|
|
TW202202153A
(zh)
|
2020-03-26 |
2022-01-16 |
美商艾羅海德製藥公司 |
用於抑制ＰＮＰＬＡ３表現之ＲＮＡｉ劑、其醫藥組成物及使用方法
|
|
IL297482A
(en)
|
2020-04-21 |
2022-12-01 |
Flagship Pioneering Inc |
Bifunctional molecules and methods of using thereof
|
|
JP2023540806A
(ja)
|
2020-09-11 |
2023-09-26 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
骨格筋への送達プラットフォームおよび使用の方法
|
|
TW202227135A
(zh)
|
2020-09-11 |
2022-07-16 |
美商愛羅海德製藥公司 |
用於遞送治療劑之脂質結合物
|
|
KR20230064620A
(ko)
|
2020-09-11 |
2023-05-10 |
애로우헤드 파마슈티컬스 인코포레이티드 |
DUX4의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
|
|
ES2990026T3
(es)
|
2020-11-18 |
2024-11-28 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular la expresión del angiotensinógeno
|
|
IL307421A
(en)
|
2021-04-08 |
2023-12-01 |
Arrowhead Pharmaceuticals Inc |
Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
|
|
IL307885A
(en)
|
2021-04-23 |
2023-12-01 |
Ganna Bio Inc |
Nucleic acids with different glycans, preparation methods and therapeutic uses
|
|
IL308883A
(en)
|
2021-05-28 |
2024-01-01 |
Arrowhead Pharmaceuticals Inc |
RNAi AGENTS FOR INHIBITING EXPRESSION OF MUCIN 5AC (MUC5AC), COMPOSITIONS THEREOF, AND METHODS OF USE
|
|
US11629349B2
(en)
|
2021-06-21 |
2023-04-18 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
|
US20250115915A1
(en)
|
2021-10-01 |
2025-04-10 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
JP2025508467A
(ja)
|
2022-02-24 |
2025-03-26 |
アイオー バイオテック エーピーエス |
癌治療のヌクレオチド送達
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
JP2025522433A
(ja)
|
2022-06-15 |
2025-07-15 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
スーパーオキシドジスムターゼ１（ＳＯＤ１）の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用の方法
|
|
AU2024240837A1
(en)
|
2023-03-21 |
2025-09-11 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of complement factor b (cfb) pharmaceutical compositions thereof, and methods of use
|
|
AU2024258561A1
(en)
|
2023-04-20 |
2025-10-30 |
Adarx Pharmaceuticals, Inc. |
Mapt-modulating compositions and methods of use thereof
|
|
WO2024238396A1
(en)
|
2023-05-12 |
2024-11-21 |
Adarx Pharmaceuticals, Inc. |
Nmda ligand conjugated compounds and uses thereof
|
|
AU2024279767A1
(en)
|
2023-05-26 |
2025-12-04 |
Adarx Pharmaceuticals, Inc. |
Sod1-modulating compositions and methods of use thereof
|
|
WO2024263694A1
(en)
|
2023-06-20 |
2024-12-26 |
Adarx Pharmaceuticals, Inc. |
Lrrk2-modulating compositions and methods of use thereof
|
|
US12503696B2
(en)
|
2023-08-30 |
2025-12-23 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025072748A2
(en)
|
2023-09-29 |
2025-04-03 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|
|
US12442002B2
(en)
|
2023-12-20 |
2025-10-14 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use
|
|
WO2025196505A2
(en)
|
2024-03-22 |
2025-09-25 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
|
|
US20250333742A1
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|